Market
Which major market will approve Orbis Medicines' first oral macrocycle drug by end of 2026?
2
Orbis Medicines•Danish•Novo Holdings•Sevan Habeshian•Christian Heinis•New Enterprise Associates•NEA•Eli Lilly•Cormorant•Forbion•Orbis•Morten Graugaard Døssing
Resolution / Starting Odds
United States • 25%
European Union • 25%
China • 25%
None • 25%
Regulatory bodies' announcements or company press releases
Story
Danish Biotech Orbis Medicines Raises €90 Million for Oral Macrocycle Drugs Targeting Biologic Therapies
Jan 6, 2025, 04:14 PM
Orbis Medicines, a Danish biotechnology startup, has raised €90 million (approximately $93 million) in a Series A funding round to develop oral macrocycle drugs. The company, incubated by Novo Holdings and co-founded by Sevan Habeshian and Christian Heinis, aims to transform popular biologic therapies into oral medications using macrocyclic peptides, targeting validated blockbuster biologic targets. The funding round was led by New Enterprise Associates (NEA) and included investments from Eli Lilly, Cormorant, the Export and Investment Fund of Denmark, and founding investors Novo Holdings and Forbion. Orbis, which emerged from stealth with €26 million in seed funding last year, is now led by CEO Morten Graugaard Døssing, who previously served as executive chair of the company's board.
View original story
Similar markets
Japan • 25%
Other • 25%
European Union • 25%
Canada • 25%
United States • 25%
China • 25%
Other • 25%
European Union • 25%
Australia • 25%
European Union • 25%
Other • 25%
United Kingdom • 25%
Other • 25%
Japan • 25%
China • 25%
European Union • 25%
Other • 25%
AstraZeneca • 25%
Roche • 25%
Pfizer • 25%
Other • 25%
China • 25%
European Union • 25%
United States • 25%
Approved in other major markets • 25%
Approved in the USA • 25%
Not approved in any major market • 25%
Approved in the EU • 25%
Eli Lilly's Zepbound • 25%
No new major approvals • 25%
A new drug from another company • 25%
Novo Nordisk's semaglutide 7.2 mg • 25%
Not approved in US or EU • 25%
Approved in US • 25%
Approved in EU • 25%
Approved in both US and EU • 25%
United States • 25%
Asia-Pacific • 25%
European Union • 25%
Other regions • 25%
Not approved in any major market • 25%
Approved in UK, EU, and USA • 25%
Approved in UK and EU • 25%
Approved in UK only • 25%
